The report "Biosimilars Market by Product (Monoclonal antibodies (infliximab, rituximab, trastuzumab), Insulin, Interferon, Etanercept, Glucagon, Calcitonin), Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region - Global Forecast to 2026" The global biosimilars market is projected to reach USD 44.7 billion by 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026. Factors such as rapid urbanization, technological advancement, increasing R&D investment by developed and developing countries, rising incidence of chronic diseases and increasing demand of biosimilars for their cost-effectiveness are driving the market.
Browse 137 market data Tables and 46 Figures spread through 253 Pages and in-depth TOC on "Biosimilars Market by Product (Monoclonal antibodies (infliximab, rituximab, trastuzumab), Insulin, Interferon, Etanercept, Glucagon, Calcitonin), Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2026 "
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html
In 2020, The monoclonal antibodies segment accounted for the largest share of the product segment in the biosimilars market.
On the basis of the product, the biosimilars market is segmented into monoclonal antibodies, insulin, granulocyte colony-stimulating factor, erythropoietin, recombinant human growth hormone, etanercept, follitropin, teriparatide, interferons, enoxaparin sodium, glucagon and calcitonin. The monoclonal antibodies product segment accounted for the largest share. Monoclonal antibodies and Insulin are seen to be the leading segments with respect to the growth rate during the forecast period due to the major factors such as increasing demand for cost-effective treatment options and wide applications of monoclonal antibodies in the treatment of cancer, autoimmune disorders and osteoporosis are driving the market.
In 2020, the oncology segment accounted for the largest share of the indication segment in the biosimilars market
On the basis of the indication, the biosimilars market is segmented into oncology, inflammatory and autoimmune diseases; chronic diseases, blood disorders; growth hormone deficiency; infectious diseases and other indications (infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases). In 2020, Oncology accounted for the largest share of the market. Factors such as increasing incidences of cancer coupled with the rising adoption of biosimilars in cancer treatments is driving the market.
The Asia Pacific region is the fastest-growing region of the biosimilars market in 2020.
On the basis of region, the biosimilars market is broadly segmented into Europe, the Asia Pacific, North America, Latin America and Middle East and Africa. In 2020, Europe is the largest regional market for biosimilars; the Asia Pacific is the second-largest regional market. Factors such as the launch of new biosimilars, the rising incidence of chronic disorders, the emergence of new players and early entry into the market, less-stringent regulations, and increasing cooperation among leading and regional players for development, manufacture and commercialization of biosimilars are driving growth in these regions.
Key players in the biosimilars market include Novartis AG (Switzerland), Pfizer, Inc. (US), Dr. Reddy’s Laboratories Ltd. (India), Amgen, Inc. (US) and Eli Lilly and Company (US).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441